New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines.

PubWeight™: 0.79‹?›

🔗 View Article (PMC 2861626)

Published in PLoS One on April 29, 2010

Authors

Teresa Rodríguez-Calvo1, Samuel Ojosnegros, Marta Sanz-Ramos, Juan García-Arriaza, Cristina Escarmís, Esteban Domingo, Noemí Sevilla

Author Affiliations

1: Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Madrid, Spain.

Articles cited by this

RNA virus mutations and fitness for survival. Annu Rev Microbiol (1997) 10.06

Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature (1985) 6.01

Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66

Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04

Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev Sci Tech (2002) 2.76

Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol (2000) 2.26

Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol (2006) 2.21

Cloning of cDNA of major antigen of foot and mouth disease virus and expression in E. coli. Nature (1981) 2.14

Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J Virol (1987) 2.02

A review of foot-and-mouth disease with special consideration for the clinical and epidemiological factors relevant to predictive modelling of the disease. Vet J (2005) 1.94

The carrier state in foot and mouth disease--an immunological review. Br Vet J (1993) 1.93

FMD vaccines. Virus Res (2003) 1.90

Protective immune response against foot-and-mouth disease. J Virol (1992) 1.77

Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A (2009) 1.72

Picornavirus nonstructural proteins: emerging roles in virus replication and inhibition of host cell functions. J Virol (1993) 1.72

Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1989) 1.71

Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol (1975) 1.70

Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61

Molecular basis of pathogenesis of FMDV. Virus Res (2003) 1.58

Evolution of foot-and-mouth disease virus. Virus Res (2003) 1.57

Extensive antigenic heterogeneity of foot-and-mouth disease virus of serotype C. Virology (1988) 1.42

A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol (1997) 1.36

A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol (2007) 1.34

Reactivity with monoclonal antibodies of viruses from an episode of foot-and-mouth disease. Virus Res (1987) 1.31

A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. J Immunol (1991) 1.31

Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine (1990) 1.29

Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26

Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology (1997) 1.24

Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol (2005) 1.22

Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine (1998) 1.16

Attenuated measles virus as a vaccine vector. Vaccine (2007) 1.13

Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine (2003) 1.13

Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol (2009) 1.12

Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol (2003) 1.10

Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol (2004) 1.09

Antibody response in pig nasal fluid and serum following foot-and-mouth disease infection or vaccination. J Hyg (Lond) (1983) 1.08

Hidden virulence determinants in a viral quasispecies in vivo. J Virol (2008) 1.06

Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol (2006) 1.00

Lessons from the foot and mouth disease outbreak in The Netherlands in 2001. Rev Sci Tech (2002) 1.00

Replication-competent foot-and-mouth disease virus RNAs lacking capsid coding sequences. J Gen Virol (2000) 0.97

Serological and mucosal immune responses after vaccination and infection with FMDV in pigs. Vaccine (2006) 0.96

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine (2009) 0.95

Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen. Virus Res (1998) 0.95

Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J Virol (2003) 0.90

Isotype-specific antibody responses to foot-and-mouth disease virus in sera and secretions of "carrier' and "non-carrier' cattle. Epidemiol Infect (1996) 0.90

Foot-and-mouth disease virus strains isolated from persistently infected cell cultures are attenuated for mice and cattle. Virus Res (1990) 0.89

A segmented form of foot-and-mouth disease virus interferes with standard virus: a link between interference and competitive fitness. Virology (2005) 0.88

Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde. Dev Biol (Basel) (2004) 0.88

Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology (2005) 0.87

Effects of chronic residence on size and size distribution of plaques of type A foot-and-mouth disease virus in primary calf kidney cell cultures. Am J Vet Res (1968) 0.85

Foot-and-mouth disease and international development. Adv Virus Res (1999) 0.83

Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone. Vaccine (1991) 0.82

Articles by these authors

Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet (2002) 4.42

Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem (2004) 2.48

A comparison of viral RNA-dependent RNA polymerases. Curr Opin Struct Biol (2005) 2.14

Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76

Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62

Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61

Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J Virol (2008) 1.60

Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58

Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. J Virol (2005) 1.57

Evolution of foot-and-mouth disease virus. Virus Res (2003) 1.57

Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56

The structure of a protein primer-polymerase complex in the initiation of genome replication. EMBO J (2006) 1.54

Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44

Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A (2007) 1.37

Quasispecies dynamics and RNA virus extinction. Virus Res (2005) 1.35

Foot-and-mouth disease virus. Comp Immunol Microbiol Infect Dis (2002) 1.33

Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A (2012) 1.32

High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene (2005) 1.31

Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A (2003) 1.27

Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26

Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol (2009) 1.22

Duration and fitness dependence of quasispecies memory. J Mol Biol (2002) 1.18

Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol (2007) 1.17

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine (2011) 1.15

Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol (2005) 1.13

Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology (2004) 1.11

Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology (2003) 1.10

A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08

Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One (2009) 1.08

Hidden virulence determinants in a viral quasispecies in vivo. J Virol (2008) 1.06

Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol (2011) 1.06

Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05

Molecular basis for a lack of correlation between viral fitness and cell killing capacity. PLoS Pathog (2007) 1.04

Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03

Viral genome segmentation can result from a trade-off between genetic content and particle stability. PLoS Genet (2011) 1.03

Arenavirus genetic diversity and its biological implications. Infect Genet Evol (2009) 1.03

Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence. PLoS One (2010) 1.02

Competition-colonization dynamics in an RNA virus. Proc Natl Acad Sci U S A (2010) 1.01

No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology (2008) 1.01

Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol (2010) 1.01

Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol (2006) 1.00

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J Virol (2002) 0.99

Resistance to extinction of low fitness virus subjected to plaque-to-plaque transfers: diversification by mutation clustering. J Mol Biol (2002) 0.98

Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10. PLoS One (2009) 0.98

Quasispecies as a matter of fact: viruses and beyond. Virus Res (2011) 0.98

Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98

Expansion of host-cell tropism of foot-and-mouth disease virus despite replication in a constant environment. J Gen Virol (2004) 0.97

Isolation of fidelity variants of RNA viruses and characterization of virus mutation frequency. J Vis Exp (2011) 0.97

Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine (2009) 0.97

Pathways to extinction: beyond the error threshold. Philos Trans R Soc Lond B Biol Sci (2010) 0.97

Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol (2002) 0.96

Selective lymphocyte depletion during the early stage of the immune response to foot-and-mouth disease virus infection in swine. J Virol (2006) 0.96

Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines (2013) 0.95

Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One (2009) 0.94

Guinea pig-adapted foot-and-mouth disease virus with altered receptor recognition can productively infect a natural host. J Virol (2007) 0.93

Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J Mol Biol (2008) 0.93

Lethal mutagenesis of viruses. Curr Opin Virol (2011) 0.92

Adaptability costs in immune escape variants of vesicular stomatitis virus. Virus Res (2005) 0.92

Evolution of cell recognition by viruses: a source of biological novelty with medical implications. Adv Virus Res (2003) 0.92

Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev (2008) 0.92

Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology (2005) 0.92

Mutation hot spots in hepatitis B surface antigen in chronic carriers from Khoozestan province, southern of Iran. Iran J Allergy Asthma Immunol (2013) 0.92

The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol (2012) 0.91

Fitness increase of memory genomes in a viral quasispecies. J Mol Biol (2004) 0.91

Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J Virol (2003) 0.90

Modeling viral genome fitness evolution associated with serial bottleneck events: evidence of stationary states of fitness. J Virol (2002) 0.90

Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol (2005) 0.90

Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol (2007) 0.90

A unique spumavirus Gag N-terminal domain with functional properties of orthoretroviral matrix and capsid. PLoS Pathog (2013) 0.90

Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol (2008) 0.89

Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol (2013) 0.88

A segmented form of foot-and-mouth disease virus interferes with standard virus: a link between interference and competitive fitness. Virology (2005) 0.88

Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. BMC Evol Biol (2008) 0.88